The company’s consolidated revenue grew by 13% year-on-year to Rs. 6,304 crore, supported by stable patient numbers and margin improvement in its hospital and retail healthcare segments.
Steady pace in core businesses
Healthcare Services (HCS) – Revenue from Apollo’s hospital business – grew 9% year-on-year to Rs. 3,169 crore, with the occupancy level rising to 69%. The company from this segment has Rs. 781 crore, up 8% YoY, while PAT rose 13% YoY to Rs. 410 crore, reflecting efficiency gains and strong patient flow for complex procedures.
The Apollo Health and Lifestyle Ltd (AHLL) segment, which operates clinics and diagnostics, continued to expand, with revenue up 17% to Rs. 474 crore and EBITDA 21% to Rs. 50 crore with growth.
Meanwhile, Apollo HealthCo, which owns the company’s digital health platform Apollo 24|7 and pharma distribution business, has raised Rs. 2,661 crore in revenue, year-on-year to Rs. 110 crore with EBITDA showing a growth of 17%. The platform has a gross merchandise value (GMV) of Rs. 723 crore, underlining Apollo’s growing digital footprint in healthcare delivery.
Live events
Chairman Dr. Pratap C Reddy said that the company’s continuous investment in technology and innovation is helping to strengthen patient care and increase operational efficiency.
“We are proud to have touched the lives and earned the trust of over 200 million people in 185 nations. Early adoption of advanced technology has resulted in over 51 lakh surgeries, 27,000 organ transplants and 22,000 robotic surgeries,” said Dr. Reddy said.
He added that Apollo is increasingly using AI-powered diagnostics and machine-learning platforms to personalize treatment for cancer and cardiovascular patients. In the quarter the company also introduced South Asia’s first AI-based music therapy at the Apollo Proton Cancer Centre, to improve the quality of life for cancer patients undergoing chemotherapy.
During the quarter, the Competition Commission of India (CCI) approved the restructuring plan of the company comprising Apollo HealthCo, KeMed and Apollo HealthTech, paving the way for Apollo to proceed with its restructuring aimed at unlocking shareholder value.
The company also reiterated that the investment intensity will remain moderate after heavy investments in recent years, although it will continue to expand its hospital capacity and clinical capabilities.
(You can now subscribe to our ETMarkets WhatsApp channel)